WGS
GeneDx Holdings Corp

4,469
Mkt Cap
$3.97B
Volume
2.15M
52W High
$170.87
52W Low
$55.17
PE Ratio
2,245.11
WGS Fundamentals
Price
$119.24
Prev Close
$135.38
Open
$130.00
50D MA
$142.82
Beta
1.58
Avg. Volume
395,182.59
EPS (Annual)
-$1.94
P/B
13.38
Rev/Employee
$305,450.00
Loading...
Loading...
News
all
press releases
GeneDx Partners With Komodo Health to Advance Rare Disease Research
WGS collaborates with Komodo Health to link genomic data with real-world insights, expanding data monetization and strengthening its role in rare disease research.
Zacks·7h ago
News Placeholder
More News
News Placeholder
GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance
GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for the fourth quarter and full year of...
Business Wire·10h ago
News Placeholder
GeneDx and Komodo Health Partner to Build the Worlds Most Complete Longitudinal Rare Disease Dataset
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, the leader in AI-powered healthcare...
Business Wire·4d ago
News Placeholder
GeneDx Announces GenomeDx Prenatal, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced GenomeDx Prenatal, whole genome sequencing (WGS) designed to deliver clear, reliable...
Business Wire·5d ago
News Placeholder
GeneDx Names Linda Genen Chief Medical Officer
(RTTNews) - GeneDx Holdings Corp. (WGS), a global leader in rare disease diagnosis, Tuesday announced appointment of Linda Genen as Chief Medical Officer...
Nasdaq News: Markets·6d ago
News Placeholder
GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights today announced Linda Genen, MD, MPH as Chief Medical Officer to further strengthen the companys...
Business Wire·6d ago
News Placeholder
GeneDx Leads Rare Disease Genomics with Unmatched Research and Clinical Impact in 2025
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a record-setting year for its Medical Affairs and research programs, reinforcing its...
Business Wire·7d ago
News Placeholder
Simplify Asset Management Inc. Sells 41,071 Shares of GeneDx Holdings Corp. $WGS
Simplify Asset Management Inc. decreased its position in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 72.4% during the 3rd quarter, according to the company in its most recent disclosure with...
MarketBeat·13d ago
News Placeholder
GeneDx to Present at the J.P. Morgan 2026 Healthcare Conference
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 44th Annual J.P. Morgan Healthcare...
Business Wire·13d ago
News Placeholder
GeneDx Holdings Corp. $WGS Shares Sold by Harbor Capital Advisors Inc.
Harbor Capital Advisors Inc. decreased its holdings in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 76.7% in the third quarter, according to its most recent filing with the Securities and...
MarketBeat·15d ago
<
1
2
...
>

Latest WGS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.